Clinical aspects of ovarian hyperstimulation syndrome

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 85, Issue 1, 1999, Pages 13-20

  Schenker, Joseph G ^a  

^a Dept Obstet Gynecol Hadassah M ^*  (Israel)

Author keywords

Cytokines; Ovarian hyperstimulation; Pregnancy; Prostaglandins; Vascular endothelial growth factor

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; DEXAMETHASONE; ENDOTHELIN 1; ESTROGEN; FOLLITROPIN; GONADORELIN AGONIST; HISTAMINE; HUMAN MENOPAUSAL GONADOTROPIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PROLACTIN; PROSTAGLANDIN DERIVATIVE; SERIC GONADOTROPIN; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGE; ASCITES; CAPILLARY PERMEABILITY; CONFERENCE PAPER; CYST RUPTURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MONITORING; MORTALITY; OVARIECTOMY; OVARY CYST; OVARY FOLLICLE FLUID; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PREGNANCY DISORDER; PREGNANCY RATE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; ULTRASOUND;

EID: 0033031526     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00276-0     Document Type: Conference Paper

References (47)

1. Schenker JG, Weinstein D Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 30:1978;3255.
2. Schenker JG. Ovarian hyperstimulation syndrome. In: Wallach EE, Zacur HA, editors. Reproductive medicine and surgery. St Louis: Mosby, l995:649.
3. Schenker JG, Polishuk WZ Role of prostaglandins in ovarian hyperstimulation syndrome. Obstet Gynecol Survey. 31:1976;742.
4. Bettendorf G Special preparations: pure FSH and desialo-hCG. Baillieres Clin Obstet Gynaecol. 4:1990;519.
5. Schenker JG Prevention and treatment of ovarian hyperstimulation. Hum Reprod. 8:1993;653.
6. Engel T, Jewelewicz R, Dyrenfurth I, Speroff L, Vande-Wiele RL Ovarian hyperstimulation syndrome: report of a case with notes on pathogenesis and treatment. Am J Obstet Gynecol. 112:1972;1052-1060.
7. Schenker JG, Polishuk WZ The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 6:1976;47-52.
8. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 63(2):1995;268-272.
9. Abramov Y, Barak V, Nisman B, Schenker JG Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril. 67:1997;261-264.
10. Ravel A, Barak V, Lavy Y, Anteby E, Abramov Y, Schenker JG, Amit A, Finci Yeheskel S, Mayer M, Simon A, Laufer N, Hurwitz A Characterization of intraperitoneal cytokines and nitrites in women with severe OHSS - a multicenter study. Fertil Steril. 66:1996;66-71.
11. Knox GE Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 118:1974;992-994.
12. Knox GE, Dowd AJ, Spiesel SA, Hong R Antihistamine blockade of the ovarian hyperstimulation syndrome, II: possible role of antigen-antibody complexes in the pathogenesis of the syndrome. Fertil Steril. 26:1975;418-421.
13. Erlik Y, Naot Y, Friedman M, Ben-David E, Paldi E Histamine levels in ovarian hyperstimulation syndrome. Obstet Gynecol. 53:1979;580-582.
14. Meirow D, Schenker JG, Rosler A Ovarian hyperstimulation syndrome with low estradiol in non-classic 17α-hydroxylase, 17,20-lyase deficiency: What is the role of estrogens? Hum Reprod. 11:1996;2119-2121.
15. Schenker JG. Prevention and managements of ovarian hyperstimulation syndrome. In: Genazzani AR, Petraglia F, Volpe A, editors. Progress in gynecology and obstetrics, Parthenon Publishing Group, 1990, pp. 661-9.
16. Pride SM, Yuen BH, Moon YS, Leung PCS Relationship of gonadotropin-releasing hormone, danasol and prostaglandin blockade to ovarian hyperstimulation syndrome in the rabbit. Am J Obstet Gynecol. 154:1986;1155-1160.
17. Borenstein R, Elchalal U, Lunenfeld B, Shoham Schwartz Z Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril. 51:1989;791-795.
18. Katz Z, Lancet M, Borenstein R, Chemke J Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil. 29:1984;186-188.
19. Shalev E, Geslevich Y, Ben-Ami M Induction of pre-ovulatory luteinizing hormone surge by gonadotropin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome. Hum Reprod. 9:1994;417-419.
20. Blumenfeld Z, Lang N, Amit A, Kahana L, Yoffe N Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction. Fertil Steril. 62:1994;456-460.
21. Gerris J, De-Vits A, Joostens M, Van-Royen E Triggering of ovulation induction in human menopausal gonadotropin-stimulated cycles: comparison between intravenously administered gonadotropin-releasing hormone (100 and 500 μg), GnRH agonist (buserelin, 500 μg) and human chorionic gonadotropin (10 000 I.U.). Hum Reprod. 10:1995;56-62.
22. McClure N, Leya J, Radwanska E, Rawlins RV, Haning RV Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod. 7:1992;758-764.
23. Frederick JL, Shimanuki T, DiZerega GS Initiation of angiogenesis by human follicular fluid. Science. 224:1984;389-392.
24. Fernandez LA, Tarlatzis BC, Rzasa QJ, Caride VJ, Laufer N, Negro-Vilar AFet al. Renin like activity in ovarian follicular fluid. Fertil Steril. 44:1985;219-223.
25. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, Schenker JG Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome. Fertil Steril. 48:1987;57-61.
26. Ong ACM, Eisen V, Rennie DP, Homburg Ret al. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endocrinol. 34:1991;43-49.
27. Pessina AC, Hulme B, Peart WS Renin-induced proteinuria and the effects of adrenalectomy, II: morphology in relation to function. Proc R Soc Lond (Biol). 180:1972;61-71.
28. Fernandez CA, Twickler J, Mead A Neovascularization produced by angiotensin II. J Lab Clin Med. 105:1985;141-145.
29. Morris RS, Wong IL, Kirkman E, Gentschein E, Paulson RJ Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod. 10:1995;1355-1358.
30. Dinarello CA Interleukin-1 and its related cytokines. Adv Immunol. 44:1989;153-205.
31. Adashi EY The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series. Endocr Rev. 11:1990;454-464.
32. Abramov Y, Schenker JG, Lewin A, Friedler S, Nisman B, Barak V Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod. 11:1996;1381-1386.
33. Buyalos RP, Watson JM, Martinez-Maza O Detection of IL-6 in human follicular fluid. Fertil Steril. 57:1992;1230-1234.
34. Hollenberg SM, Cunnion RE, Parillo JE The effect of tumor necrosis factor on vascular smooth muscle. Chest. 100:1991;1133-1137.
35. Preiser JC, Schmartz D, Van der Linden P, Content J, Van den Buxxche P, Buurman Wet al. IL-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine. 3:1991;1-4.
36. Prado GN, Thomas KM, Suzuki H, La Rosa GJ, Wilkinson N, Folco E, Navarro J Molecular characterization of a novel rabbit interleukin-8 receptor isotype. J Biol Chem. 269:1994;1239-1241.
37. Balasch J, Arroyo V, Carmona F, Llach J, Jimenez W, Pare JCet al. Severe ovarian hyperstimulation syndrome: role of peripheral vasodilatation. Fertil Steril. 56:1991;1077-1083.
38. Filep JG, Sirois MG, Foldes-Filep E, Rousseau A, Plante GE, Fournier Aet al. Enhancement by endothelin-1 of microvascular permeability via the activation of ETA receptors. Br J Pharmacol. 109:1993;880-886.
39. Kamada S, Kubota T, Taguchi M, Aso T High levels of immunoreactive endothelin-1 in human follicular fluids. Hum Reprod. 8:1993;674-677.
40. Krasnow JS, Berga SL, Gusick DS, Zeleznik AJ, Yeo KT Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril. 65:1996;552-555.
41. Mucheler EK, Kohler D, Huang KE Monitoring of ovulation induction with HMG-HCG therapy by plasma estrogen and progesterone. Int J Fertil. 26:1981;273-278.
42. Gemzel C Induction and ovulation. Acta Obset Gynecol Scand (Suppl). 47:1976;1.
43. Tulandy T, MvInnes R, Arronet G Ovarian hyperstimulation syndrome, following ovulation induction with human menopausal gonadotropin. Int J Fertil. 29:1984;113-117.
44. Schenker JG, Lewin A, Ben-David M. Principles of pathophysiology of infertility assessment and treatment. In: Kurjak A, editor. Ultrasound and infertility, CRC, Boca Raton, FL, 1989:23-33.
45. Schenker JG, Schumert Z, Shifrin A, Spitz I. Steroid pattern of experimental hyperstimulation syndrome and the response to indomethacin. Presented at the Second International Congress of Human Reproduction, Tel Aviv, 1977.
46. Rabinowitz R, Laufer N, Lewin Aet al. Rate of ovarian hyperstimulation syndrome after high dose HMG for induction of ovulation in IVF cycles. 5th congress on IVF-ET Norfolk, USA, Abstract. 500:1987;111.
47. Magnus O, Tanbo T, Abyholm T Severe hyperstimulation syndrome, Case reports. Acta Eur Fertil. 19:1988;89-92.